BioPhenoMA participated in the BIO International Convention 2026, held from June 22–25, 2026, at the San Diego Convention Center in California, USA. The company exhibited within the JETRO Japan Pavilion (Booth No. 4421-21). Throughout the event, we welcomed a wide range of visitors, including representatives from pharmaceutical companies, academia, and CROs. Interest in our technologies was exceptionally high, particularly in the area of exosome analysis, which continues to a

Strengthening International Collaboration for Novel Biomarker Discovery Using NK Cell–Derived Exosomes BioPhenoMA Inc. has signed a Memorandum of Understanding (MOU) with Taiwan Exosome Co. Ltd., (Taiwan) and Waseda University to promote international collaboration in the discovery of novel biomarkers using exosomes. This partnership aims to advance diagnostic technologies based on immune cell–derived exosomes and strengthen research networks between Japan and Taiwan. Exosom

BioPhenoMA Inc. will exhibit at the BIO International Convention 2026, held June 22–25, 2026, in San Diego, California. We develop IDAP (Integrated Dynamics Analysis Platform), a research infrastructure that enables measurement of real‑specimen protein dynamics while preserving micro‑volume, localization, and temporal changes. Our ultra‑sensitive immunoassay TN‑cyclon™ quantifies proteins down to 0.1 pg/mL, revealing biological signals that conventional technologies cannot de

BioPhenoMA Inc. presented the results of its joint research with Waseda University at the International Society for Extracellular Vesicles (ISEV) 2026 Annual Meeting. This study focused on GRP78 contained in small extracellular vesicles (sEVs) induced by the anticancer drug 5-FU, and utilized our proprietary high‑sensitivity protein quantification technology, TN‑cyclon™, to analyze trace levels of GRP78 and its functional impact. The aim was to clarify how 5-FU treatment alte

We are pleased to announce that the results of our collaborative research with Waseda University will be presented at ISEV 2026 , one of the world’s leading conferences in extracellular vesicle (EV) research. In this study, we utilized BioPhenoMA’s proprietary ultra‑sensitive protein quantification technology, TN‑cyclon™ , to explore the biological roles of extracellular vesicles in the field of oncology. Our aim is to generate new insights into EV‑mediated mechanisms, partic

“BioPhenoMA launches collaborative research program utilizing ultra‑sensitive protein quantification technology; open call for partners across academia and industry.” https://www.nikkan.co.jp/articles/view/00775428 For more details, please visit the Research Call section on our website.

BioPhenoMA Inc. (Shinjuku-ku, Tokyo; President and CEO: Daisuke Niwa) has extended the expiration date of its research reagent kits, which use its proprietary ultra-trace protein quantification technology "TN-cyclon™," from two months to six months. To meet growing global research needs, such as exosome membrane/lumen localization information analysis and trace protein dynamics analysis, the company has established a supply system suitable for overseas transportation, invento

BioPhenoMA Inc. has launched a full-scale contract research service for protein analysis using its proprietary ultra-trace protein quantification technology "TN-cyclon™" for a variety of actual samples, including blood, urine, saliva, and sputum. This service provides a comprehensive range of services, from pretreatment, extraction, fractionation, antibody selection, and measurement system construction to highly sensitive quantification at the 0.1 pg/mL level, as well as kine

We exhibited at Bio Japan (October 8-10, at Pacifico Yokohama) and the Japanese Society for Extracellular Vesicles (JSEV) (October 14-15, at Osaka). We introduced our business activities to date and exhibited related topics, and on both occasions we were able to explain to the many visitors, leading to lively Q&A sessions and information exchanges. We were also able to obtain many business leads that could potentially lead to future business development. We would like to once

We are currently exhibiting at a booth at BioJapan, which is being held at Pacifico Yokohama. Please stop by when you visit. [BioJapan...

We are planning to exhibit at a booth at BioJapan, which will be held at Pacifico Yokohama from Wednesday, October 8th to Friday, October...

The highly sensitive protein quantification technology "TN-cyclon™ ELISA Kit" developed and provided by BioPhenoMA Co., Ltd. has been...

BioPhenoMA Inc. (headquarters: Shinjuku-ku, Tokyo) is pleased to announce that Director Makoto Mitamura has been appointed as the new...

A paper on the establishment of an ultrasensitive detection assay for sEV-derived PD-L1 as a serum biomarker for lung cancer - a pilot...

Sales of the "TN-cyclon™ ELISA Development Kit" have begun. Order page: https://www.funakoshi.co.jp/contents/72027 [Please visit the...

Funakoshi Co., Ltd. sells PD-L1 measurement kits using TN-cyclon™ technology, as well as kits for ultra-low-volume protein analysis...

BioPhenoMA launches the new ultra-sensitive protein detection reagent kit (Product Name: “TN-cyclon™ ELISA Development Kit”) for research...

The Article about our new reagent kit for research was published in The Nikkan Kogyo Shimbun. Read the article (Japanese):...

Journal of Cellular Immunology Vol. 7 (January issue) published our article “ GRP78: A Multifaceted Role in Cancer Progression and...

BioPhenoMA has been selected as one of the companies in the Health category of the Winter/Spring 2025 Q1 Batch accelerator program by...